|
|
|
Volumn 26, Issue 4, 1999, Pages 439-447
|
|
Immunologic approaches to the treatment of prostate cancer
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCG VACCINE;
CANCER VACCINE;
CYCLOPHOSPHAMIDE;
CYTOKINE;
GAMMA INTERFERON;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
INTERLEUKIN 1BETA;
LIPID A;
ONCOVAX P;
PROSTATE SPECIFIC ANTIGEN;
RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
RECOMBINANT INTERLEUKIN 2;
TUMOR NECROSIS FACTOR ALPHA;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ARTICLE;
CANCER IMMUNOTHERAPY;
CELLULAR IMMUNITY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DRUG SAFETY;
FEMALE;
HUMAN;
HUMORAL IMMUNITY;
IMMUNE RESPONSE;
IMMUNE SYSTEM;
IMMUNIZATION;
IMMUNOLOGICAL TOLERANCE;
INTRADERMAL DRUG ADMINISTRATION;
INTRAMUSCULAR DRUG ADMINISTRATION;
INTRAVENOUS DRUG ADMINISTRATION;
MALE;
PRIORITY JOURNAL;
PROSTATE CANCER;
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
TUMOR IMMUNITY;
CANCER VACCINES;
CLINICAL TRIALS;
HUMANS;
IMMUNOTHERAPY;
INTERLEUKINS;
LIPOSOMES;
MALE;
NEOPLASMS, HORMONE-DEPENDENT;
PROSTATIC NEOPLASMS;
|
|
EID: 0032825107
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (80)
|
|
References (47)
|
